Mitchell R. Smith, MD, PhD

Articles

Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCL

July 26th 2021

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Dr. Smith on the Rationale of the ECOG-ACRIN E1411 Trial in MCL

July 16th 2021

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Dr. Smith on the Results of the ECOG-ACRIN E1411 Trial in MCL

June 9th 2021

Mitchell R. Smith, MD, PhD, discusses the results of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL

December 10th 2019

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Dr. Smith on PI3K Inhibitors in CLL

November 2nd 2019

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Smith on Frontline Treatment Considerations in CLL

October 24th 2019

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

October 17th 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Smith on Utilizing Lenalidomide in CLL

October 4th 2019

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

Dr. Smith on Ibrutinib-Based Therapies in CLL

September 23rd 2019

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.

Dr. Smith on Emerging Therapies in Indolent Lymphoma

September 11th 2019

Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.